A new regulation just adopted by the Council of the EU will give the UK Medicines and Healthcare products Regulatory Agency (MHRA) responsibility for approving innovative new medicines on a UK-wide basis, making it easier for pharmaceutical companies to market such products in Northern Ireland.
This means that eventually new centralized EU marketing authorizations will no longer be valid in Northern Ireland, as they currently are under the Northern Ireland Protocol, and that medicines approved by the MHRA will be available in Northern Ireland at the same
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?